2025年7月7日，波士顿科学公司（纽约证券交易所代码：BSX）宣布，其Farapulse脉冲场消融（PFA）系统已获美国食品药品监督管理局（FDA）批准，扩展其标签适用范围，新增对药物难治性、有症状的持续性心房颤动（AFib）的治疗许可。Farapulse系统作为治疗AFib的领先PFA技术之一，于去年首次获得FDA批准，通过导管精准输送脉冲场能量，靶向消融心脏异常组织，从而恢复心脏正常节律。...
Source Link2025年7月7日，波士顿科学公司（纽约证券交易所代码：BSX）宣布，其Farapulse脉冲场消融（PFA）系统已获美国食品药品监督管理局（FDA）批准，扩展其标签适用范围，新增对药物难治性、有症状的持续性心房颤动（AFib）的治疗许可。Farapulse系统作为治疗AFib的领先PFA技术之一，于去年首次获得FDA批准，通过导管精准输送脉冲场能量，靶向消融心脏异常组织，从而恢复心脏正常节律。...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.